[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT06793683":3,"trial-entities:NCT06793683":134,"trial-summary:NCT06793683":139},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":12,"sponsor_name":13,"lead_sponsor_class":14,"has_dmc":15,"brief_summary":16,"detailed_description":17,"conditions":18,"keywords":20,"study_type":26,"primary_purpose":27,"phases":28,"enrollment_info":30,"interventions":33,"primary_outcomes":46,"secondary_outcomes":55,"sex":64,"minimum_age":65,"maximum_age":66,"healthy_volunteers":15,"eligibility_criteria":67,"std_ages":86,"locations":89,"central_contacts":99,"overall_officials":100,"references":104,"see_also_links":133},"NCT06793683","STUDY00018758","Early BOTOX After Spinal Cord Injury","Early Detrusor Chemodenervation to Preserve Bladder Compliance and Longevity After Spinal Cord Injury","ENROLLING_BY_INVITATION","2028-09-30","2024-12","2025-01-27","2024-07-27","University of Washington","OTHER",false,"The investigators would like to improve our understanding of how early intervention with the use of bladder chemodenervation can preserve bladder function in those with a new SCI. Although detrimental cystometric and tissue changes are known to occur, often within 3 months after SCI, the investigators seek to document the time course of these changes and the range of severity of those changes in both those participants that receive prophylactic treatment and those who do not.",null,[19],"Spinal Cord Injuries",[21,22,23,24,25],"SCI","Neurogenic Bladder","Chemodenervation with BoNT-A","Botox","Autonomic Dysreflexia","INTERVENTIONAL","PREVENTION",[29],"EARLY_PHASE1",{"count":31,"type":32},10,"ESTIMATED",[34,40],{"type":35,"name":36,"description":37,"armGroupLabels":38},"DRUG","Bladder chemodenervation (Botox)","BoNT-A (Botox) 200 U will be injected into the detrusor (bladder wall muscle).",[39],"Bladder Chemodenervation (Botox) Injection Procedure",{"type":41,"name":42,"description":43,"armGroupLabels":44},"PROCEDURE","Bladder Sham (Saline) Injection Procedure","20mL placebo (saline only), will be injected into the detrusor (bladder wall muscle).",[45],"Bladder Sham (saline) Injection Procedure",[47,51],{"measure":48,"description":49,"timeFrame":50},"Feasibility of Enrollment goals","Outcomes of this pilot trial will provide human data on the feasibility of recruiting 10 participants into a randomized study of early chemodenervation.\n\nThe enrollment goal is 10 participants who will complete the 12-month study protocol.\n\nIf ≥ 8 participants complete the protocol, it will be considered feasible. If ≤ 5 participants complete the protocol, it will be considered unfeasible. If 6-7 participants complete the study, it will be considered indeterminate.","Each participant will be evaluated for a period of up to 12 months after the time of enrollment.",{"measure":52,"description":53,"timeFrame":54},"Number of participants with treatment-related adverse events as assessed by CTCAE v4.0","Patients will be monitored for adverse events as a result of the procedures.\n\n* Evidence of Urinary Tract Infections\n* Hematuria\n* Anesthesia Complications\n\nAny adverse events (AE) will be graded 1 through 5, with unique clinical descriptions of severity for each AE, based upon the AE guidelines as published in the CAE v4.0","For each participant any AE's will be documented, at time of AE, beginning at study enrollment and throughout each participants 12 month enrollment period.",[56,60],{"measure":57,"description":58,"timeFrame":59},"Variance of measurements for functional data","Determination of variance of measurements for functional data, including:\n\nCystometric values will be analyzed as a continuous variable and compared between early detrusor oBoNT-A injected cases and controls at the 6- and 12-month time points. Standard clinical care characterizes bladder compliance as poor for values \\\u003C10 mL\u002Fcm H2O, indeterminate for values between 10 mL\u002Fcm H2O and 20 mL\u002Fcm H2O, and good for values \\>20 mL\u002Fcm H2O. To interpret our data, we will use these existing clinical guidelines in concert with statistical differences that arise.","Variances of all measurements and data, for each subject, will be analyzed at the conclusion of their study participation, 12 months post enrollment.",{"measure":61,"description":62,"timeFrame":63},"Variance of measurements for histological data","Determination of variance of measurements for histological data, including:\n\nHistological analyses of the bladder biopsy samples will include standard histological staining to evaluate hypertrophy and fibrosis, and how these parameters change with time (baseline, 6 months and 12 months post SCI).","Variances of all measurements and data will be analyzed at the conclusion of the study (expected in 2028).","ALL","18 Years","65 Years",{"inclusion":68,"exclusion":75,"raw_text":85},[69,70,71,72,73,74],"Male or female 18-65 years of age at time of SCI.","English speaking","Recent SCI (within 20 weeks of injury).","Documentation of a spinal cord injury at T6 or higher, American Spinal Injury Association Impairment Scale (AIS) level A or B as designated on initial (72 hour) AIS exam.","Ability for subject to comply with the requirements of the study.","Written informed consent obtained from subject.",[76,77,78,79,80,81,82,83,84],"Inability to return to research site (Harborview Medical Center) for follow-up studies after initial hospitalization.","Acute (as part of concurrent hospitalization) or history of bladder surgery (urethral or prostate surgery acceptable) or injury.","Inability to provide informed consent.","Pregnant, breastfeeding, or unwilling to practice birth control during participation in the study.","Incarcerated in a detention facility or in police custody.","Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.","Active medical problems precluding the safe conduct of urodynamics, bladder chemodenervation, bladder biopsy (e.g., evidence of active bladder infection, ruled out by urine culture prior to procedures)","Known hypersensitivity to any botulinum toxin preparation or to any of the components in the formulation","Cardiovascular instability","Inclusion Criteria:\n\n* Male or female 18-65 years of age at time of SCI.\n* English speaking\n* Recent SCI (within 20 weeks of injury).\n* Documentation of a spinal cord injury at T6 or higher, American Spinal Injury Association Impairment Scale (AIS) level A or B as designated on initial (72 hour) AIS exam.\n* Ability for subject to comply with the requirements of the study.\n* Written informed consent obtained from subject.\n\nExclusion Criteria:\n\n* Inability to return to research site (Harborview Medical Center) for follow-up studies after initial hospitalization.\n* Acute (as part of concurrent hospitalization) or history of bladder surgery (urethral or prostate surgery acceptable) or injury.\n* Inability to provide informed consent.\n* Pregnant, breastfeeding, or unwilling to practice birth control during participation in the study.\n* Incarcerated in a detention facility or in police custody.\n* Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.\n* Active medical problems precluding the safe conduct of urodynamics, bladder chemodenervation, bladder biopsy (e.g., evidence of active bladder infection, ruled out by urine culture prior to procedures)\n* Known hypersensitivity to any botulinum toxin preparation or to any of the components in the formulation\n* Cardiovascular instability",[87,88],"ADULT","OLDER_ADULT",[90],{"facility":91,"city":92,"state":93,"zip":94,"country":95,"geoPoint":96},"Harborview Medical Center","Seattle","Washington","98104","United States",{"lat":97,"lon":98},47.60621,-122.33207,[],[101],{"name":102,"affiliation":13,"role":103},"Claire C Yang, MD","PRINCIPAL_INVESTIGATOR",[105,109,112,115,118,121,124,127,130],{"pmid":106,"type":107,"citation":108},"16517054","BACKGROUND","Comperat E, Reitz A, Delcourt A, Capron F, Denys P, Chartier-Kastler E. Histologic features in the urinary bladder wall affected from neurogenic overactivity--a comparison of inflammation, oedema and fibrosis with and without injection of botulinum toxin type A. Eur Urol. 2006 Nov;50(5):1058-64. doi: 10.1016\u002Fj.eururo.2006.01.025. Epub 2006 Feb 6.",{"pmid":110,"type":107,"citation":111},"22503020","Ginsberg D, Gousse A, Keppenne V, Sievert KD, Thompson C, Lam W, Brin MF, Jenkins B, Haag-Molkenteller C. Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity. J Urol. 2012 Jun;187(6):2131-9. doi: 10.1016\u002Fj.juro.2012.01.125. Epub 2012 Apr 12.",{"pmid":113,"type":107,"citation":114},"16317536","Ku JH, Choi WJ, Lee KY, Jung TY, Lee JK, Park WH, Shim HB. Complications of the upper urinary tract in patients with spinal cord injury: a long-term follow-up study. Urol Res. 2005 Dec;33(6):435-9. doi: 10.1007\u002Fs00240-005-0504-4. Epub 2005 Nov 30.",{"pmid":116,"type":107,"citation":117},"9776015","Janzen J, Vuong PN, Bersch U, Michel D, Zaech GA. Bladder tissue biopsies in spinal cord injured patients: histopathologic aspects of 61 cases. Neurourol Urodyn. 1998;17(5):525-30. doi: 10.1002\u002F(sici)1520-6777(1998)17:53.0.co;2-f.",{"pmid":119,"type":107,"citation":120},"29352989","Bywater M, Tornic J, Mehnert U, Kessler TM. Detrusor Acontractility after Acute Spinal Cord Injury-Myth or Reality? J Urol. 2018 Jun;199(6):1565-1570. doi: 10.1016\u002Fj.juro.2018.01.046. Epub 2018 Jan 17.",{"pmid":122,"type":107,"citation":123},"37096828","Rosier PFWM, Valdevenito JP, Smith P, Sinha S, Speich J, Gammie A; Members of the ICS Working Group PFS23. ICS-SUFU standard: Theory, terms, and recommendations for pressure-flow studies performance, analysis, and reporting. Part 1: Background theory and practice. Neurourol Urodyn. 2023 Nov;42(8):1590-1602. doi: 10.1002\u002Fnau.25192. Epub 2023 Apr 25.",{"pmid":125,"type":107,"citation":126},"24518764","Welk B, Morrow S, Madarasz W, Baverstock R, Macnab J, Sequeira K. The validity and reliability of the neurogenic bladder symptom score. J Urol. 2014 Aug;192(2):452-7. doi: 10.1016\u002Fj.juro.2014.01.027. Epub 2014 Feb 8.",{"pmid":128,"type":107,"citation":129},"24708598","Tang DH, Colayco D, Piercy J, Patel V, Globe D, Chancellor MB. Impact of urinary incontinence on health-related quality of life, daily activities, and healthcare resource utilization in patients with neurogenic detrusor overactivity. BMC Neurol. 2014 Apr 4;14:74. doi: 10.1186\u002F1471-2377-14-74.",{"pmid":131,"type":107,"citation":132},"36356027","Bushnell JY, Cates LN, Hyde JE, Hofstetter CP, Yang CC, Khaing ZZ. Early Detrusor Application of Botulinum Toxin A Results in Reduced Bladder Hypertrophy and Fibrosis after Spinal Cord Injury in a Rodent Model. Toxins (Basel). 2022 Nov 10;14(11):777. doi: 10.3390\u002Ftoxins14110777.",[],{"nct_id":4,"conditions":135,"biomarkers":138},[136,22,137],"Autonomic dysreflexia","Spinal Cord Injury",[],{"nct_id":4,"found":15,"summary":17,"prompt_version":17}]